Anti-proliferative effect of lapatinib in HER2-positive and HER2-negative/HER3-high breast cancer: results of the pre-surgical randomized MAPLE trial (CRUK E/06/039)Alexandra Leary,
نویسندگان
چکیده
1 Institut de Cancerologie, Gustave Roussy, France 2 Poole Hospital NHS Foundation Trust, Poole, UK 3 The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK 4 The Institute of Cancer Research – Clinical Trials and Statistics Unit, Division of Clinical Studies, Sutton, UK 5 DNA Electronics Ltd, London, UK 6 Academic Department of Biochemistry, Royal Marsden NHS Foundation Trust, London, UK 7 Maidstone and Tunbridge Wells NHS Foundation Trust, Kent, UK 8 University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
منابع مشابه
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
PURPOSE Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for responsive versus nonresponsive tumors. EXPERIMENTAL DESIGN Women with primary breast cancer were randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial (ISRCTN68509377). Biopsies pre-/posttreatment were analyzed ...
متن کاملPersonalized Medicine and Imaging Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Purpose: Not all breast cancers respond to lapatinib. A change in Ki67 after short-term exposure may elucidate a biomarker profile for responsive versus nonresponsive tumors. ExperimentalDesign:Womenwith primary breast cancerwere randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial (ISRCTN68509377). Biopsies pre-/posttreatment were analyzed for ...
متن کاملHeregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
BACKGROUND Overexpression of heregulin, a HER3 ligand, is one mechanism that confers resistance to the anti-HER2 agents trastuzumab and lapatinib. We investigated the impact of heregulin expression on the efficacy of HER2-targeted therapeutic agents, including trastuzumab, trastuzumab emtansine (T-DM1) and lapatinib, in vitro and in vivo and evaluated the heregulin messenger RNA (mRNA) levels i...
متن کاملCancer Therapy: Preclinical Dual Blockade of HER2 inHER2-Overexpressing TumorCells Does Not Completely Eliminate HER3 Function
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approach. Inhibition of HER2 and downstream phosphoinositide 3-kinase (PI3K)/AKT causes a transcriptional and posttranslational upregulation of HER3 whic...
متن کاملDual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
PURPOSE The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive breast cancer that is refractory to anti-HER2 therapy. The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance. EXPERIMENTAL DESIGN We analyzed in vitro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014